Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/24915
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-03-08T11:51:38Z | - |
dc.date.available | 2022-03-08T11:51:38Z | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Gürel, S. ve Kıyıcı, M. (2005). "Ulcerative colitis activity index: a useful prognostic factor for predicting ulcerative colitis outcome". Journal of International Medical Research, 33(1), 103-110. | en_US |
dc.identifier.issn | 0300-0605 | - |
dc.identifier.uri | https://doi.org/10.1177/147323000503300111 | - |
dc.identifier.uri | https://journals.sagepub.com/doi/10.1177/147323000503300111 | - |
dc.identifier.uri | http://hdl.handle.net/11452/24915 | - |
dc.description.abstract | We evaluated the usefulness of various parameters in predicting the prognosis of ulcerative colitis. The records of 73 patients with ulcerative colitis were examined retrospectively. Patients were divided into two groups according to whether they had received only 5-aminosalicylic acid (5-ASA; n = 26) or glucocorticoids and/or azathioprine with or without 5-ASA (n = 47). The disease extent, endoscopic activity and ulcerative colitis activity index (UCAI) before therapy were recorded, together with the disease outcome. No statistically significant differences in outcome were observed in relation to therapy group, disease extent or endoscopic activity. UCAI had a significant effect on outcome, however: patients with lower UCAI values were more likely to remain in remission and less likely to require urgent surgery or experience a fatal outcome than those with higher UCAI values. This difference was apparent in both treatment groups. Thus a high pre-treatment UCAI may indicate a worse outcome. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Research & experimental medicine | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Ulcerative colitis activity index | en_US |
dc.subject | Predictive factor | en_US |
dc.subject | Ulcerative colitis | en_US |
dc.subject | Outcome | en_US |
dc.subject | Inflammatory bowel-disease | en_US |
dc.title | Ulcerative colitis activity index: A useful prognostic factor for predicting ulcerative colitis outcome | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000225986500011 | tr_TR |
dc.identifier.scopus | 2-s2.0-13444270994 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-3208-6211 | tr_TR |
dc.identifier.startpage | 103 | tr_TR |
dc.identifier.endpage | 110 | tr_TR |
dc.identifier.volume | 33 | tr_TR |
dc.identifier.issue | 1 | tr_TR |
dc.relation.journal | Journal of International Medical Research | en_US |
dc.contributor.buuauthor | Gürel, Selim | - |
dc.contributor.buuauthor | Kıyıcı, Murat | - |
dc.contributor.researcherid | AAI-4213-2021 | tr_TR |
dc.identifier.pubmed | 15651722 | tr_TR |
dc.subject.wos | Medicine, research & experimental | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 7003706434 | tr_TR |
dc.contributor.scopusid | 6507627491 | tr_TR |
dc.subject.scopus | Ulcerative Colitis; Golimumab; Infliximab | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Disease activity | en_US |
dc.subject.emtree | Disease duration | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Erythrocyte sedimentation rate | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gastrointestinal endoscopy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Kaplan meier method | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Remission | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Statistical analysis | en_US |
dc.subject.emtree | Statistical significance | en_US |
dc.subject.emtree | Survival rate | en_US |
dc.subject.emtree | Ulcerative colitis | en_US |
dc.subject.emtree | Azathioprine | en_US |
dc.subject.emtree | Glucocorticoid | en_US |
dc.subject.emtree | Mesalazine | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Gürel_Kıyıcı_2005.pdf | 59.29 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License